The News Review:
- Immune cells cause more post-stroke brain damage-study
- Arrowhead Senior Advisors Featured in Nature and Nature Medicine …
- Scientists learn why even treated genital herpes sores boost the …
- Post-transplant Combo Can Replace Toxic Immune-suppressing Drugs …
- Common allergy medicine to fight diabetes and obesity?
- Breast cancer discovery heralds diagnosis hope
Immune cells cause more post-stroke brain damage-study
so the sooner the intervention (blocking of IL-23) happens the more protective it is for the brain" he said. The experts hope to apply the findings of the study published in Nature Medicine on people. "Most patients come to hospital within a day after a stroke so we need to develop a therapeutic method to prevent the expansion of infarction" Yoshimura said. "ur study is important because it provides a therapeutic target. We should start to treat patients one day after stroke happens (to block the infiltration of immune cells). " He added that an experimental antibody against interleukin-23 is currently in phase 2 clinical trial.
Arrowhead Senior Advisors Featured in Nature and Nature Medicine …
Nanotechnology News (press release) (press release)
and Chad Mirkin Ph. were featured in the July 2009 editions of both Nature Medicine and Nature magazines for their outstanding work in nanomedicine. Arrowhead Senior Advisors Featured in Nature and Nature Medicine ArticlesPASADENA CA | Posted on July 31st 2009he Nature article titled “Big opportunities in a small world” may be viewed at: www.
Scientists learn why even treated genital herpes sores boost the …
EurekAlert (press release)
Scientists have uncovered details of an immune-cell environment conducive to HIV infection that persists at the location of HSV-2 genital skin lesions long after they have been treated with oral doses of the drug acyclovir and have healed and the skin appears normal. These findings are published in the advance online edition of Nature Medicine on Aug. Led by Lawrence Corey M.
Related from International-lifestyles: To reduce the risk of genital herpes use a condom — every time
Post-transplant Combo Can Replace Toxic Immune-suppressing Drugs …
Science Daily (press release)
The non-human primate research was conducted at the National Institutes of Health and Yerkes National Primate Research Center Emory University. The results are published in the July issue of Nature Medicine. The finding opens the door to less-toxic post-transplant treatment that could be administered once a week rather than a dizzying mound of pills every day says senior author Allan Kirk MD PhD scientific director of the Emory Transplant Center and a Georgia Research Alliance Eminent Scholar. "Both of the drugs used in this regimen are already used separately in humans thus a clinical trial could be developed quickly" Kirk notes. ne key ingredient in the combination is an experimental therapy called a costimulation blocker designed to interfere with the T cells that cause graft rejection without affecting other organs. Costimulation refers to one of two signals T cells need from other cells (antigen presenting cells) to become fully activated.
Common allergy medicine to fight diabetes and obesity?
According to the Asthma and Allergy Foundation an estimated 50 million Americans also suffer from some sort of allergy. Could common over the counter allergy medication be the next treatment for metabolic conditions such as type 2 diabetes and obesity? Researchers from Harvard Medical School think so. A group of papers appearing in. Although chronic inflammation in the body has already been linked to heart disease cancer and Alzheimer’s disease this latest research gives us a better understanding of the relationship between inflammation and metabolic disorders.
Classic carnival rides at amusements.com
Breast cancer discovery heralds diagnosis hope
The breakthrough research came from the study of a unique collection of breast cancer tissue donated by Australian women. It is expected to benefit women from families that are particularly prone to the disease as well those who get the ??basal?? form of the cancer which is particularly aggressive and the least responsive to current treatments. A team led by associate professors Jane Visvader and Geoff Lindeman from the Walter and Eliza Hall Institute made the discovery which was published this morning in the international journal Nature Medicine. They investigated samples donated through the research network kConFab by women who have had breast surgery to fight or avoid cancer. The samples were mostly from the 10 per cent of women who have genetically inherited a much higher risk of breast cancer. Those with the ??BRCA1 mutation?? have a 65 per cent chance of developing breast cancer in their lifetime. The researchers were searching for the original cells that malfunction to begin the spread of cancer.